A new blood test for advanced prostate cancer
Official title: Validation of predictive liquid biomarkers for patients with metastatic prostate cancer
Funded at University of Wisconsin-Madison · NIH-11087719 · Data updated 2026-11-12
This project aims to develop a new blood test to help doctors quickly identify when prostate cancer is becoming resistant to treatment.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project start | June 1, 2021 |
| Project end | May 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $328,747 |
| NIH project number | 5UH3CA260389-05 |
| Project ID | NIH-11087719 on NIH RePORTER |
Who could benefit from this research
✓Could help
This research is for patients with metastatic prostate cancer, especially those whose cancer has become resistant to initial hormone-blocking treatments.
✕Less likely to help
Patients with early-stage prostate cancer or those who have not yet received treatment for advanced disease may not directly benefit from this specific biomarker test.
What this research studies
Many men with advanced prostate cancer benefit from initial treatments, but their cancer often becomes resistant over time, which can lead to delays in finding the right next treatment. Our goal is to create a simple blood test that looks for specific signs in circulating tumor cells. This test could help doctors understand sooner if your cancer is changing, allowing them to adjust your treatment plan more quickly. The hope is to improve how we manage prostate cancer that has become resistant to standard therapies.
Why it matters
Potential benefit: If successful, this new blood test could help patients with advanced prostate cancer receive more effective treatments sooner, potentially improving their survival and quality of life.
How similar studies have gone: While the concept of liquid biopsies is gaining traction, this specific biomarker assay for treatment-resistant prostate cancer is undergoing rigorous validation to establish its clinical utility.
Where this research is happening
-
University of Wisconsin-Madison
Madison, United States Active
Researchers
- Principal investigator: Lang, Joshua — University of Wisconsin-Madison
- Study coordinator: Lang, Joshua
Related research
Other NIH-funded projects on the same topics.
-
Combination immunotherapy with radioligand therapy for metastatic prostate cancer
A study aims to help men with advanced prostate cancer by combining immune therapy with targeted radiation to boost the body’s own defense against cancer.
-
Understanding what drives lethal metastatic prostate cancer in men
This grant looks at why some prostate cancers become deadly and spread, using patient-derived cells and mouse models.
-
Off-the-shelf tumor cell vaccine tailored to your tumor’s HLA type for advanced prostate cancer
A new vaccine approach uses donor cancer cells matched to a patient’s immune system to help fight advanced prostate cancer.
-
ASH1L’s role in metastatic prostate cancer and its immune environment
Aims to understand how the ASH1L gene helps prostate cancer spread and how it shapes the immune environment in bone metastases so future therapies can target this process.
-
Molecular drivers of lineage changes and new therapies for metastatic prostate cancer
A multi-year study at a major university will explore how metastatic prostate cancer changes its cell type and how to target those changes to help patients.
-
How gut bacteria may affect prostate cancer therapy and resistance
A new study looks at how gut bacteria make compounds that influence prostate cancer treatments and may drive resistance to therapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.